# US 2013/0157951 A1 · Pharmaceutical Composition Containing Goserelin for In-Situ Implant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157951 A1
- Document ID: US20130157951A1
- Status: Published application
- Kind: A1
- Application number: 13/805,624
- Filed: 2011-06-24
- Published: 2013-06-20
- Earliest claimed: 2010-06-24
- Assignees: Torrent Pharmaceuticals Limited
- Inventors: Sunil S. Nadkarni; Jaya Abraham; Amit Kesarwani; Astha Parmar
- Web page: https://patentgrep.com/patent/US20130157951A1

## CPC

- A61K 38/25: Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a pharmaceutical composition capable of forming in-situ implant comprising goserelin or its pharmaceutically acceptable salts thereof, biodegradable polymer and a biocompatible organic solvent wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid. The present invention further provides a process for the preparation of pharmaceutical composition capable of forming in-situ implant. A kit containing composition for in-situ implant is provided comprising a first vial comprising a composition comprising a biodegradable polymer and a biocompatible organic solvent; wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid; and a second vial comprising goserelin acetate.

## Claims

### Claim 1

A pharmaceutical composition capable of forming in-situ implant comprising: goserelin or its pharmaceutically acceptable salts thereof, biodegradable polymer and a biocompatible organic solvent wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid.

### Claim 2 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the biodegradable polymer is aseptically dried either by lyophilization or spray drying prior to mixing with biocompatible organic solvent.

### Claim 3 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the biodegradable polymer is selected from the group comprising of polylactides, polyglycolides, polycaprolactones, polydioxannones, polycarbonates, polyhydroxybutyrates, polyalkyene oxalates, polyanhydrides, polyamides, polyesteramides, polyurethanes, polyacetals, polyketals, polyorthocarbonates, polyphosphazenes, polyhydroxyvalerates, polyalkylene succinates, poly(malic acid), poly(amino acids), chitin, chitosan, polyorthoesters, and copolymers, terpolymers, block copolymers, branched copolymers, and mixtures thereof.

### Claim 4 (depends on 3)

The pharmaceutical composition as claimed in claim 3 wherein the biodegradable polymer is selected from the group comprising of polylactides, polyglycolides, copolymer of lactic acid and glycolic acid, polycaprolactones, or their mixtures thereof.

### Claim 5 (depends on 4)

The pharmaceutical composition as claimed in claim 4 wherein the biodegradable polymer is copolymer of lactic acid and glycolic acid.

### Claim 6 (depends on 5)

The pharmaceutical composition as claimed in claim 5 wherein the copolymer of lactic acid and glycolic acid is having a carboxyl terminal group or ester terminal group.

### Claim 7 (depends on 5)

The pharmaceutical composition as claimed in claim 5 wherein copolymer of lactic acid and glycolic acid is having a carboxyl terminal group.

### Claim 8 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the amount of biodegradable polymer is between about 20% to about 80% by weight of the composition.

### Claim 9 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the amount of biodegradable polymer is between about 30% to about 50% by weight of the composition.

### Claim 10 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein biocompatible organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone (NMP), 2-pyrrolidone, propylene carbonate, ethylene carbonate, dimethyl carbonate, 2-ethyoxylyl acetate, ethyl acetate, methyl acetate, ethyl lactate, ethyl butyrate, diethyl malonate, diethyl glutonate, tributyl citrate, diethyl succinate, tributyrin, isopropyl myristate; dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, glyceryl triacetate, acetone, methyl ethyl ketone, solketal, glycerol formal, glycofurol, dimethylformamide, dimethylacetamide, dimethylsulfoxide (DMSO), dimethylsulfone; tetrahydrofuran; epsilon-caprolactone, butyrolactone, caprolactam, N,N-dimethyl-m-toluamide, 1-dodecylazacycloheptan-2-one, benzyl alcohol, benzyl benzoate, triacetin or mixtures thereof.

### Claim 11 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the biocompatible organic solvent is N-methyl-2-pyrrolidone (NMP).

### Claim 12 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the biocompatible organic solvent is a mixture N-methyl-2-pyrrolidone (NMP) and benzyl benzoate.

### Claim 13 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the biocompatible organic solvent is present in about 20% to about 80% by weight of the composition.

### Claim 14 (depends on 1)

The pharmaceutical composition as claimed in claim 1 wherein the biocompatible organic solvent is present in about 50% to about 70% by weight of the composition.

### Claim 15

A process for the preparation of pharmaceutical composition capable of forming in-situ implant comprising following steps:
1. Preparing goserelin solution in suitable solvent, sterilizing the solution by suitable technique and subsequent lyophilizing in a suitable container;
2. Separately sterilizing biodegradable polymer and biocompatible organic solvent by suitable technique, and filling the mixture into a suitable container.

### Claim 16

A process for the preparation of pharmaceutical composition capable of forming in-situ implant comprising following steps:
1. Preparing goserelin solution in suitable solvent, sterilizing the solution by membrane filtration and subsequent lyophilizing in a suitable container;
2. Dissolving biodegradable polymer in a suitable solvent and sterilizing by membrane filtration technique and lyophilized;
3. Biocompatible organic solvent is sterilizing separately by membrane filtration technique;
4. Mixing polymer and solvent of step 2 & 3 and filling in a suitable container.

### Claim 17

A kit containing composition for in-situ implant comprising (a) a first vial comprising a composition comprising a biodegradable polymer and a biocompatible organic solvent; wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body fluid; and (b) a second vial comprising goserelin acetate.

### Claim 18 (depends on 17)

The kit as claimed in claim 17 wherein the goserelin acetate is in lyophilized form.

### Claim 19 (depends on 1)

The pharmaceutical composition as claimed in claim 1 is for once a month administration.

### Claim 20 (depends on 1)

The pharmaceutical composition as claimed in claim 1 is for once in three months administration.

### Claim 21 (depends on 1)

The pharmaceutical composition as claimed in claim 1 is for once in two months administration.
